Reading HALO? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track HALO free→Reading HALO? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track HALO free→QuarterlyIQ Insights · HALO
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
of this report and shall not be deemed “ filed ” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, (the “ Exchange Act ” ) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. (c) On April 30, 2026, Halozyme Therapeutics, Inc. (the “Company”) announced that Darren Snellgrove has been appointed to serve as the Company’s Chief Financial Officer (“CFO”), effective June 8, 2026. Since May 2025, Mr. Snellgrove (age 52) has served as Vice President, Investor Relations at Johnson & Johnson, a multinational pharmaceutical, biote…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. (c) On March 12, 2026, Halozyme Therapeutics, Inc. (the “Company”) announced that David Ramsay has been appointed to serve as the Company’s Interim Chief Financial Officer (“Interim CFO”), effective March 23, 2026. Since April 2017, Mr. Ramsay (age 61) has served as a member of the Board of Directors of Savara Inc., a clinical-stage biopharmaceutic…
of this report and shall not be deemed “ filed ” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, (the “ Exchange Act ” ) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. (c) On October 1, 2025, Cortney Caudill was appointed as Senior Vice President, Chief Operating Officer of Halozyme Therapeutics, Inc. (the “Company”), effective immediately. Ms. Caudill (age 49) has served as the Company’s Senior Vice President, Chief Operations Officer since October 2023. Prior to joining the Company, from 2019 to October 2023, M…
Entry into a Material Definitive Agreement. On September 30, 2025, Halozyme Therapeutics, Inc., a Delaware corporation (“ Halozyme ”), entered into an Agreement and Plan of Merger (the “ Merger Agreement ”) with Elektrofi, Inc., a Delaware corporation (“ Elektrofi ”), Erraid Merger Sub Inc., a Delaware corporation and a wholly-owned subsidiary of Halozyme (“ Merger Sub ”), and Shareholder Representative Services LLC, a Colorado limited liability company (the “ Securityholders’ Representative…
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.